Compositions comprising antineoplastons and methods of treating breast cancer

The combination of antineoplastons and targeted therapies in breast cancer treatment effectively addresses the limitations of current therapies by reducing metastases and improving patient outcomes, offering a more comprehensive management of breast cancer.

WO2024263643A1PCT designated stage expired Publication Date: 2024-12-26BURZYNSKI STANISLAW R
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/034623
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-19
Filing Date
2024-06-19
Publication Date
2024-12-26

AI Technical Summary

Technical Problem

Current treatments for breast cancer, particularly metastatic breast cancer, are inadequate in effectively managing the disease and reducing metastases, as evidenced by the high mortality rates and limited therapeutic options.

Method used

The use of compositions comprising antineoplastons, such as AS2-1 and A10, in combination with targeted therapies like abemaciclib, ado-trastuzumab emtansine, and others, to administer a therapeutically effective treatment regimen that targets specific cancer cells and reduces genomic aberrations, thereby preventing and decreasing metastases.

Benefits of technology

This approach demonstrates a tumor and molecular response, preventing and decreasing metastases, prolonging survival, and improving the quality of life by reducing the need for additional therapeutic agents and surgical interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000027_0001
    Figure IMGF000027_0001
  • Figure IMGF000028_0001
    Figure IMGF000028_0001
  • Figure IMGF000028_0002
    Figure IMGF000028_0002
Patent Text Reader

Abstract

Disclosed herein are compositions comprising one or more antineoplastons and using those compositions in methods of treating breast cancer, prolonging the survival of a subject, and preventing and / or decreasing metastasis of breast cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Method of predicting response to therapy by assessing tumor genetic heterogeneity

    US20210002719A1

  • Pharmaceutical composition for subcutaneous injection comprising human hyaluronidase PH20 variant and drug

    US20220289864A1